EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Laurent Peyrin-Biroulet 1, 2
Marla C. Dubinsky 3
Bruce E. Sands 3
Julian Panés 4
Stefan Schreiber 5
Walter Reinisch 6
Brian G. Feagan 7, 8
Silvio Danese 9
Andres Yarur 10
Geert R. D'Haens 11
Martina Goetsch 12
Karolina Wosik 13
Joseph Wu 14
Irene Modesto 15
Aoibhinn McDonnell 16
Lauren Bartolome 17
Christopher J. Rabbat 17
Severine Vermeire 18
1 University of Lorraine, CHRU-Nancy, Nancy, France
2 University of Lorraine, Inserm, NGERE, Nancy, France
3 Icahn School of Medicine at Mount Sinai, New York, United States
4 Formerly Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
5 University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
6 Medical University of Vienna, Vienna, Austria
7 Western University, London, Canada
8 Alimentiv Inc, London, Canada
9 IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
10 Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, United States
11 Amsterdam University Medical Centers, Amsterdam, Netherlands
12 Pfizer AG, Zürich, Switzerland
13 Pfizer Canada, Kirkland, Canada
14 Pfizer Inc, Groton, United States
15 Pfizer Inc, Madrid, Spain
16 Pfizer Ltd, Sandwich, United Kingdom
17 Pfizer Inc, New York, United States
18 University Hospitals Leuven, Leuven, Belgium
Topic
IBD
Conference
UEG Week Copenhagen 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]